Searchable abstracts of presentations at key conferences in endocrinology

ea0048wf8 | Workshop F: Disorders of the parathyroid glands, calcium metabolism and bone | SFEEU2017

A case of transient hypercalcemia

Kumar Rakshit , Rodin Andrew

We are presenting a common case of diagnostic dilemma with hypercalcemia.This 66 year female patient was referred to Endocrine clinic with hypercalcemia. She was asymptomatic with blood tests showing C.Calcium of 2.73 mmol/l. This was followed by investigations to rule out primary or tertiary hyperparathyroidism.Blood tests revealed high PTH of 12.2 pmol/l with low 25OH Vitamin D of 37 nmol/l, suggesting a diagnosis of tertiary hyp...

ea0055cb16 | Additional Cases | SFEEU2018

DHEA: is it fountain of youth or medical need?

Kumar Rakshit , Hafeez Saba , Velusamy Anand

We present here a case of 70 year old female, seen in endocrine clinic for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression after prolonged glucocorticoid use. History revealed that she had prolonged use of prednisolone for her asthma in the past. In 2011, Prednisolone was stopped but she had to be started on Hydrocortisone replacement due to HPA axis suppression. She was taking Hydrocortisone 20 mg BD. Trials to wean her off Hydrocortisone failed due to ongoing tiredness...

ea0048we4 | Workshop E: Disorders of the gonads | SFEEU2017

Amenorrhoea in disorder of sexual development

Kumar Rakshit , Thurston Layla , Rodin Andrew

We present here a case of diagnostic dilemma in a 34-year female presenting with Amenorrhoea. She was recently married and saw GP for infertility and history of hot flushes, melasma and migraine. Clinic history revealed primary amenorrhoea diagnosed in Brazil at age 15. Patient was told she was born without ovaries and was started on Premarin (oetrogen). She had normal female secondary sexual charcteristics, functional female genitalia and growth. On examination, she had a nor...

ea0073aep841 | Late Breaking | ECE2021

Natural course and surveillance of non-functioning pituitary microadenomas

Iyer Rishi , Kumar Rakshit , Velusamy Anand

In the current era of multi-modal imaging being performed for various pathologies, incidental non-functioning pituitary microadenomas (NFPAs) are being increasingly identified. The available literature and guidance is limited on the long-term surveillance and monitoring and hence there is a wide variation in clinical practice across the UK. We conducted a retrospective study in our institution to compare the outcome in our cohort to the current literature.<p class="abstext...

ea0055wc2 | Workshop C: Disorders of the thyroid gland (I) | SFEEU2018

Toxic nodule: wait or treat?

Hafeez Saba , Kumar Rakshit , Velusamy Anand , Powrie Jake , Carroll Paul

68 years old female initially referred to endocrine clinic in November 2016 for assessment of fluctuating thyroid function. She had a history of long standing primary hypothyroidism, stable on treatment with 100 mcg Levothyroxine. In last one year, Levothyroxine was tapered and stopped due to persistent suppression of TSH and high normal Free T4. Last tests showed TSH of <0.01mIU/l and Free T4 of 27.1 pmol/l. She had ongoing complaints of feeling increasingly tired and gen...

ea0063p430 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Efficacy of DHEA in improving Quality of Life in prolonged HPA axis suppression from exogenous steroids

Anandappa Samantha , Kumar Rakshit , Breen Louise , Thakali Sonu , Tam Maria , Magtoto Cynthia , Carroll Paul , Velusamy Anand

Dehydroepiandrosterone (DHEA) has been a subject of controversy for more than a decade being called ‘a miracle hormone’, the ‘elixir of life’ and ‘an anti-aging supplement’. However, recent literature has proven mild to moderate benefit in selected group of patients. Data is mostly limited to primary adrenal failure patients with adequate glucocorticoid and mineralocorticoid replacement and in hypopituitarism from variable aetiology associated wit...

ea0056p139 | Endocrine tumours and neoplasia | ECE2018

Prevalence of undiagnosed Medullary Thyroid Carcinoma and Phaeochromocytoma in MEN2A syndrome revealed by cascade screening

Kumar Rakshit , Joshi Mamta , Velusamy Anand , Mcgowan Barbara , Powrie Jake , Izatt Louise , Carroll Paul

Mutations in the RET gene are responsible for Multiple Endocrine Neoplasia type 2A (MEN2A), characterised by Medullary Thyroid Carcinoma (MTC) and Pheochromocytoma (PCC). It is well recognised that there is a genotype-phenotype correlation regarding likelihood of endocrine tumour development. The American Thyroid Association (ATA) has published predictive grading to guide clinical management of patients with RET mutations.Aim: In this study, we aim to as...